Overview
Plain-language guide
An oral cholesterol-lowering medicine for the FDA-labeled adult population.
It helps the liver retain more LDL receptors, allowing more LDL cholesterol to be removed from the blood.
Clinical mechanism
Inhibits PCSK9 to increase LDL-receptor availability and lower LDL cholesterol.
Applications
Human evidence
Multiple human studies and regulatory review support at least one product-specific indication.
Tier 1Preclinical evidence
Mechanistic and preclinical findings are tracked separately and are not treated as proof of human clinical benefit.
Regulatory status
Approved. United States: Lipfendra as an adjunct to diet and exercise to reduce LDL cholesterol in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia.
Safety
Known but Manageable Risks
- Adverse effects vary by product and indication
- Contraindications and interactions require label review
Interactions
Review the current product label and indication-specific literature for pharmacologic and absorption interactions.
Treatment pattern
Treatment patterns are product-, indication- and clinician-specific; this educational profile does not provide dosing guidance.
Manufacturing and quality
Approved-product identity, formulation and quality controls must not be extrapolated to compounded or RUO copies.
Sponsor and development history
Merck · FDA approved. Development programs and ownership can change; confirm current sponsor disclosures.
Sources
2026-07-17: FDA announcement of the first approved oral PCSK9 inhibitor.
- 01FDA: Lipfendra approval announcement ↗
Regulator · 2026-07-17
Gaps and unverified claims
- Evidence must be interpreted by indication and product label.
- Approval does not establish safety or efficacy for off-label or compounded copies.
Last reviewed
September 23, 2026 (listed facts only) · Primary-source check needed